Julian Rathke, H. S. Menezes, Raul Ivo Rossi-Filho, J. L. Manica
{"title":"经皮闭塞持续动脉导管","authors":"Julian Rathke, H. S. Menezes, Raul Ivo Rossi-Filho, J. L. Manica","doi":"10.1590/0104-1843000000061","DOIUrl":null,"url":null,"abstract":"Background: Patent ductus arteriosus is a congenital condition with high morbidity, especially in preterm infants of extremely low birth weight, representing 5% to 10% of congenital heart diseases. Our objective was to describe the approaches used at a reference hospital for the percutaneous occlusion of PDA. Methods: We conducted a retrospective study on the transcatheter treatment of patent ductus arteriosus from April of 2008 to April of 2010. Results: Forty-seven cases were reviewed and most of them (78.8%) were treated with FlipperTM coils while the remaining patients received the AmplatzerTM device. Ductal morphological configuration was Krichenko type A in 89.4% (34 in the FlipperTM coil group and 8 in the AmplatzerTM group), type D in 6.4% (2 in the FlipperTM coil group and 1 in the AmplatzerTM group) and type E in 4.2% (1 in each group) of patients. Pre-catheterization minimum diameters were 2.6 ± 0.8 mm and 3.8 ± 1.6 mm for the FlipperTM coil and AmplatzerTM groups, respectively. Immediate total occlusion of the defect was obtained in the control angiography in 72.3% of the patients. Seven patients treated with the FlipperTM coil received additional coils and two patients treated with the AmplatzerTM device presented minimal residual shunts. There were no procedure-related complications. In the follow-up after hospital discharge, one patient presented minimal residual shunt at the echography, 45 days after catheterization. Conclusions: Percutaneous patent ductus arteriosus occlusion has proven to be safe and effective in most cases.","PeriodicalId":101093,"journal":{"name":"Revista Brasileira de Cardiologia Invasiva","volume":"93 1","pages":"364-368"},"PeriodicalIF":0.0000,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Oclusão Percutânea da Persistência do Ducto Arterioso\",\"authors\":\"Julian Rathke, H. S. Menezes, Raul Ivo Rossi-Filho, J. L. Manica\",\"doi\":\"10.1590/0104-1843000000061\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Patent ductus arteriosus is a congenital condition with high morbidity, especially in preterm infants of extremely low birth weight, representing 5% to 10% of congenital heart diseases. Our objective was to describe the approaches used at a reference hospital for the percutaneous occlusion of PDA. Methods: We conducted a retrospective study on the transcatheter treatment of patent ductus arteriosus from April of 2008 to April of 2010. Results: Forty-seven cases were reviewed and most of them (78.8%) were treated with FlipperTM coils while the remaining patients received the AmplatzerTM device. Ductal morphological configuration was Krichenko type A in 89.4% (34 in the FlipperTM coil group and 8 in the AmplatzerTM group), type D in 6.4% (2 in the FlipperTM coil group and 1 in the AmplatzerTM group) and type E in 4.2% (1 in each group) of patients. Pre-catheterization minimum diameters were 2.6 ± 0.8 mm and 3.8 ± 1.6 mm for the FlipperTM coil and AmplatzerTM groups, respectively. Immediate total occlusion of the defect was obtained in the control angiography in 72.3% of the patients. Seven patients treated with the FlipperTM coil received additional coils and two patients treated with the AmplatzerTM device presented minimal residual shunts. There were no procedure-related complications. In the follow-up after hospital discharge, one patient presented minimal residual shunt at the echography, 45 days after catheterization. Conclusions: Percutaneous patent ductus arteriosus occlusion has proven to be safe and effective in most cases.\",\"PeriodicalId\":101093,\"journal\":{\"name\":\"Revista Brasileira de Cardiologia Invasiva\",\"volume\":\"93 1\",\"pages\":\"364-368\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Brasileira de Cardiologia Invasiva\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1590/0104-1843000000061\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Brasileira de Cardiologia Invasiva","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/0104-1843000000061","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Oclusão Percutânea da Persistência do Ducto Arterioso
Background: Patent ductus arteriosus is a congenital condition with high morbidity, especially in preterm infants of extremely low birth weight, representing 5% to 10% of congenital heart diseases. Our objective was to describe the approaches used at a reference hospital for the percutaneous occlusion of PDA. Methods: We conducted a retrospective study on the transcatheter treatment of patent ductus arteriosus from April of 2008 to April of 2010. Results: Forty-seven cases were reviewed and most of them (78.8%) were treated with FlipperTM coils while the remaining patients received the AmplatzerTM device. Ductal morphological configuration was Krichenko type A in 89.4% (34 in the FlipperTM coil group and 8 in the AmplatzerTM group), type D in 6.4% (2 in the FlipperTM coil group and 1 in the AmplatzerTM group) and type E in 4.2% (1 in each group) of patients. Pre-catheterization minimum diameters were 2.6 ± 0.8 mm and 3.8 ± 1.6 mm for the FlipperTM coil and AmplatzerTM groups, respectively. Immediate total occlusion of the defect was obtained in the control angiography in 72.3% of the patients. Seven patients treated with the FlipperTM coil received additional coils and two patients treated with the AmplatzerTM device presented minimal residual shunts. There were no procedure-related complications. In the follow-up after hospital discharge, one patient presented minimal residual shunt at the echography, 45 days after catheterization. Conclusions: Percutaneous patent ductus arteriosus occlusion has proven to be safe and effective in most cases.